<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04802785</url>
  </required_header>
  <id_info>
    <org_study_id>1</org_study_id>
    <nct_id>NCT04802785</nct_id>
  </id_info>
  <brief_title>The Impact of Air Travel on Passenger Cognitive Functions</brief_title>
  <official_title>The Impact of Air Travel on Passenger Cognitive Functions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dinara Zhumanbayeva</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>lurye Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the period from June 2021 to June 2022, a prospective clinical study will be conducted in&#xD;
      the Republic of Kazakhstan with economy class passengers traveling by plane with a minimum&#xD;
      flight period of 5-7 flight hours in the territory of the Republic of Kazakhstan.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2021</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Urine Specific Gravity</measure>
    <time_frame>24 hours before the flight</time_frame>
    <description>Urine Specific Gravity test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SpO2 level</measure>
    <time_frame>24 hours before the flight</time_frame>
    <description>Pulse oximetry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ultrasound examination</measure>
    <time_frame>24 hours before the flight</time_frame>
    <description>Ultrasound examination of the veins of the lower limbs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Liverpool Jet Lag questionnaire</measure>
    <time_frame>24 hours before the flight</time_frame>
    <description>Changes from normal (0 to 5) while jetlag rating was recorded on a scale from 0 = insignificant jetlag to 10 = severe jetlag</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lake Louise Acute Mountain Sickness Assessment System</measure>
    <time_frame>24 hours before the flight</time_frame>
    <description>Mild acute mountain sicknessas 3-5 points, moderate acute mountain sickness as 6-9 points, and severe acute mountain sickness as 10-12 points</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neuropsychological tests (Trail Making Test, Wechsler Memory Scale - IV, Free recall</measure>
    <time_frame>24 hours after the flight</time_frame>
    <description>Word, color, and color-word T-Scores of 40 or less are considered &quot;low.&quot; Word, color, and color-word T-Scores above 40 or are considered &quot;normal.&quot; In order for one score to be considered &quot;higher&quot; or &quot;lower&quot; than another, a 10 point or greater T score difference is required.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Liverpool Jet Lag questionnaire (LJLQ)</measure>
    <time_frame>24 hours after the flight</time_frame>
    <description>Changes from normal (0 to 5) while jetlag rating was recorded on a scale from 0 = insignificant jetlag to 10 = severe jetlag</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lake Louise Acute Mountain Sickness Assessment System</measure>
    <time_frame>24 hours after the flight</time_frame>
    <description>Mild acute mountain sicknessas 3-5 points, moderate acute mountain sickness as 6-9 points, and severe acute mountain sickness as 10-12 points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Stroop Test</measure>
    <time_frame>24 hours after the flight</time_frame>
    <description>Word, color, and color-word T-Scores of 40 or less are considered &quot;low.&quot; Word, color, and color-word T-Scores above 40 or are considered &quot;normal.&quot; In order for one score to be considered &quot;higher&quot; or &quot;lower&quot; than another, a 10 point or greater T score difference is required.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine Specific Gravity</measure>
    <time_frame>24 hours after the flight</time_frame>
    <description>Urine Specific Gravity test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SpO2 level</measure>
    <time_frame>24 hours before the flight</time_frame>
    <description>Pulse oximetry</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Air Travel</condition>
  <arm_group>
    <arm_group_label>The study Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Before the flight in the conditions of the clinic's medical treatment room: Citicoline 500 mg(Vitaae®) and Cytochrome10 mg (Cytochrome C®) per os.&#xD;
30 minutes before the flight: dilute 1 sachet of ORS® (Sodium Chloride 2.6 g+Potassium Chloride 1.5 g+Sodium Citrate 2.90 g+Dextrose 13.5 g) in 1 liter of water. Drink half of the solution (0.5 l) 30 minutes before the flight (at the airport). Also, 0.5 L of the solution will be provided on the plane during landing. If the flight lasts more than 1.5 hours, then dilute the second sachet of ORS® with 0.5-1 liters of water.&#xD;
30 minutes before the flight (per os): Domperidone (Motilium ®) (1 tablet), Simethicone (Gas-X®) (3-4 capsules), Acetylsalicylic acid 150 mg and magnesium hydroxide 30,39 mg (Cardiomagnyl®)(1 tablet), probiotic (Bactistatin®) (1 capsule) per os.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Melatonin® 5 mg per os 2 hours before bedtime on the day of arrival for 3-4 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Explanatory group:</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>12 participants without any intervention.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Citicoline</intervention_name>
    <description>Citicoline 500 mg (Vitaae®) per os</description>
    <arm_group_label>The study Group</arm_group_label>
    <other_name>Citicoline (Vitaae®)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytochrome C6</intervention_name>
    <description>Cytochrome10 mg per os</description>
    <arm_group_label>The study Group</arm_group_label>
    <other_name>(Cytochrome C®)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Chloride Oral Product</intervention_name>
    <description>Sodium Chloride (NaCl) 2.6 g. per os</description>
    <arm_group_label>The study Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Potassium Chloride Oral Product</intervention_name>
    <description>Potassium Chloride 1.5 g per os</description>
    <arm_group_label>The study Group</arm_group_label>
    <other_name>Potassium Chloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Citrate Oral Product</intervention_name>
    <description>Sodium Citrate 2.90 g per os</description>
    <arm_group_label>The study Group</arm_group_label>
    <other_name>Sodium Citrate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dextrose Oral Tablet, Chewable</intervention_name>
    <description>Dextrose 13.5 g per os</description>
    <arm_group_label>The study Group</arm_group_label>
    <other_name>Dextrose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Domperidone Oral Product</intervention_name>
    <description>Domperidone 1 tablet per os</description>
    <arm_group_label>The study Group</arm_group_label>
    <other_name>Motilium ®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simethicone</intervention_name>
    <description>3-4 capsules per os</description>
    <arm_group_label>The study Group</arm_group_label>
    <other_name>Gas-X®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetylsalicylic acid</intervention_name>
    <description>Acetylsalicylic acid 150 mg per os</description>
    <arm_group_label>The study Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Magnesium hydroxide</intervention_name>
    <description>magnesium hydroxide 30 mg per os</description>
    <arm_group_label>The study Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Probiotic Formula</intervention_name>
    <description>1 capsule per os.</description>
    <arm_group_label>The study Group</arm_group_label>
    <other_name>Bactistatin®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melatonin 5 mg</intervention_name>
    <description>Melatonin 5 mg per os.</description>
    <arm_group_label>Control group</arm_group_label>
    <other_name>Natrol Melatonin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Study participants (Volunteers) will be recruited through media, advertisements and&#xD;
        announcements. Prior to the study, study participants will receive written and oral&#xD;
        explanations of the study protocols, and written informed consent will be obtained from&#xD;
        each study participant. All potential research participants will undergo medical and&#xD;
        psychological selection. The components, stages of selection are almost the same as those&#xD;
        of general professional selection: the first stage is professiography / psychogram, the&#xD;
        second stage is psychodiagnostics, the third stage is assessment and forecasting, and the&#xD;
        fourth stage is decision making. Selection will assess the ability of participants to&#xD;
        perform complex sequential actions.&#xD;
&#xD;
        Inclusion criterion:&#xD;
&#xD;
          -  Age from 22 to 30 years old;&#xD;
&#xD;
          -  at least 15 years of education, including secondary education;&#xD;
&#xD;
          -  understand and speak Russian (Due to the valid Russian-language questionnaire and&#xD;
             methodology).&#xD;
&#xD;
        In addition, study participants will be asked not to limit their caffeine intake from their&#xD;
        daily intake, but only water is allowed 4 hours before the neuropsychological testing.&#xD;
        Participants in the study should not hmedical/medicallane in the last two weeks prior to&#xD;
        the start of the study, nor should they consume alcohol during the study.&#xD;
&#xD;
        Exclusion criterion:&#xD;
&#xD;
          -  A member taking melatonin (affects circadian rhythm);&#xD;
&#xD;
          -  Participant with comorbidities that affect cognitive function and sleep (eg, stroke,&#xD;
             TIA, concussion with loss of consciousness, hearing problems, chronic fatigue&#xD;
             syndrome, depression, seasonal affective disorder, anorexia);&#xD;
&#xD;
          -  A participant with another ongoing sleep disorder.&#xD;
&#xD;
        All participants must be free of a history of venous thrombosis, antithrombotic or&#xD;
        anticoagulant medications and oral contraceptives and / or any other drugs that interfere&#xD;
        with blood coagulation (i.e. warfarin, coumadin) for at least 2 months prior to study&#xD;
        initiation, and sign a consent to refrain from taking medications that may affect&#xD;
        coagulation, such as aspirin or non-steroidal anti-inflammatory drugs, within 3 days after&#xD;
        the flight, unless there is a medical / medical need.&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Arman Lurye</last_name>
    <phone>+7 701 765 2196</phone>
    <email>arman@lurye.clinic</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dinara Dzhumanbayeva</last_name>
    <phone>+7 701 765 2196</phone>
    <email>dinara@lurye.clinic</email>
  </overall_contact_backup>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 17, 2021</study_first_submitted>
  <study_first_submitted_qc>March 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 17, 2021</study_first_posted>
  <last_update_submitted>March 15, 2021</last_update_submitted>
  <last_update_submitted_qc>March 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>lurye Clinic</investigator_affiliation>
    <investigator_full_name>Dinara Zhumanbayeva</investigator_full_name>
    <investigator_title>head of laboratory</investigator_title>
  </responsible_party>
  <keyword>Air Travel</keyword>
  <keyword>health</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Domperidone</mesh_term>
    <mesh_term>Melatonin</mesh_term>
    <mesh_term>Cytidine Diphosphate Choline</mesh_term>
    <mesh_term>Simethicone</mesh_term>
    <mesh_term>Magnesium Hydroxide</mesh_term>
    <mesh_term>Citric Acid</mesh_term>
    <mesh_term>Sodium Citrate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

